The Phase Gate
Graveyard
90% of drug candidates die before reaching patients. Billions buried at every phase gate. Can you see which of your drugs are headed for the graveyard?
The Phase Gate Graveyard
Where 90% of drug candidates go to die—and billions get buried
The Billion-Dollar Burial Ground
Every failed phase transition isn't just a scientific setback—it's capital permanently interred.
The Phase II Massacre
Phase II is where dreams die. 69% of drugs that enter Phase II never make it out. That's $58M average per burial.
The Phase III Price Tag
By the time a drug fails in Phase III, you've invested $314M on average. One failure can crater your quarterly guidance.
Pipeline Visibility Gap
Your board sees pipeline counts. They don't see probability-weighted value. A "15-drug pipeline" means nothing without survival rates.
The Oncology Graveyard
Oncology has a 5.9% success rate from Phase I to approval. If you're in oncology, 94% of your pipeline is destined for graves.
You Report Pipeline Counts. Investors Want Risk-Adjusted Value.
A Phase I drug and a Phase III drug are not equal. But your board deck probably treats them the same. Without probability-weighted pipeline visualization, you're presenting fantasy, not reality.
Analyst asks: 'What's your pipeline worth?'
You present: '15 drugs in development'
They calculate: '15 × 10% = 1.5 expected approvals'
Stock drops: 'Pipeline is overvalued'
Phase Transition Survival Rates
Source: BIO/Informa Pharma Intelligence Clinical Development Success Rates
See Which Drugs Are Headed for the Graveyard
Risk-adjusted pipeline visualization that tells the real story of your drug portfolio.
Risk-Adjusted Pipeline
Every drug shown with its phase-specific success probability. A Phase III drug isn't worth the same as Phase I. Your board will finally see reality.
See Pipeline ViewGate-by-Gate Tracker
Real-time visibility into phase transitions. See which drugs are approaching gates, which are stalling, and which are showing red flags.
See Gate AnalysisBuried vs. Invested
Track exactly how much capital has been buried in failed drugs vs. invested in survivors. Show investors you're not throwing money into graves.
See Capital FlowGraveyard by Indication
Some graveyards are bigger than others. Oncology, CNS, immunology—see survival rates by therapeutic area and adjust expectations accordingly.
See TA AnalysisPipeline Metrics That Actually Matter
Stop counting drugs. Start measuring probability-weighted value.
Risk-Adjusted NPV
Pipeline value weighted by phase-specific success probability. The only honest pipeline metric.
Phase Transition Rate
Your historical success rate at each gate vs. industry benchmarks. Are you better or worse?
Time-to-Phase
How long drugs spend in each phase. Delays predict failures. Speed predicts survival.
Capital at Risk
How much is invested in drugs currently at high-risk phases. Board needs to know exposure.
Expected Approvals
Pipeline count × historical success rate = what will actually reach patients.
Graveyard Cost
Total capital buried in failed drugs this year. The honest cost of R&D.
Real CMO Scenarios
The Analyst Day Pipeline Presentation
Analyst day is next month. You need to present pipeline value. Your IR team is counting drugs. Analysts will discount by 90%. You look either naive or deceptive.
SlideStrike generates risk-adjusted pipeline view automatically. Phase-weighted NPV, expected approvals, historical transition rates. Analysts see you understand the graveyard. Credibility preserved.
The Phase III Failure Announcement
Your lead Phase III just failed. Board meeting tomorrow. How do you explain $340M buried? How do you show the pipeline can recover?
One slide showing capital flow: invested vs. buried vs. remaining. Another showing risk-adjusted portfolio value without the failed drug. Board sees the hit is priced in. Forward guidance protected.
The M&A Pipeline Valuation
Acquirer wants to see your pipeline. They are sending their own analysts. Your internal valuations will be shredded if they are not risk-adjusted.
Export risk-adjusted pipeline analysis directly from SlideStrike. Phase-specific probabilities, indication-specific benchmarks, capital at risk by gate. You look like you know what you have.
Connects to Your R&D Systems
SlideStrike pulls pipeline data from your existing infrastructure.
Pipeline Mgmt
Veeva Vault, Planisware
Portfolio Tools
Clarivate, Evaluate
Clinical Data
Medidata, Oracle
Regulatory
Veeva RIM, MasterControl
Financial
SAP, Oracle Financials
Intelligence
Citeline, GlobalData
Analytics
Spotfire, Power BI
CRM/IR
Salesforce, Ipreo
Pipeline Questions Answered
Real questions from pharmaceutical executives
QHow do you calculate phase success probabilities?
We use industry benchmarks from BIO/Informa studies, adjusted for your specific therapeutic area, indication, and biomarker status.
QCan we customize success rates based on our internal data?
Yes. SlideStrike allows you to input your historical phase transition rates for more accurate portfolio modeling.
QHow does this help with investor communications?
Risk-adjusted pipeline views show investors the real expected value, not just drug counts. This builds credibility and sets realistic expectations.
QCan we model different scenarios?
Yes. SlideStrike supports scenario planning for different success rates, timeline assumptions, and portfolio decisions.
QWhat data sources do you use?
We integrate with clinical trial registries, regulatory databases, and your internal CTMS/portfolio systems.
See Your Pipeline's True Survival Odds
Stop presenting fantasy pipeline counts. Show risk-adjusted reality.
See My Pipeline Analysis